MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9

[1]  C. Cordon-Cardo,et al.  A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. , 2013, The American journal of pathology.

[2]  Hua-mei Tang,et al.  Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma , 2013, Clinical & Experimental Metastasis.

[3]  Y. Akao,et al.  Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. , 2013, Cancer letters.

[4]  Paul Hofman,et al.  Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC , 2013, PloS one.

[5]  R. Dahiya,et al.  Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer , 2012, PloS one.

[6]  R. Dahiya,et al.  MicroRNA-1280 Inhibits Invasion and Metastasis by Targeting ROCK1 in Bladder Cancer , 2012, PloS one.

[7]  U. Bhawal,et al.  Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer , 2012, British Journal of Cancer.

[8]  N. Seki,et al.  Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. , 2012, Urologic oncology.

[9]  N. Seki,et al.  Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. , 2012, International journal of oncology.

[10]  N. Seki,et al.  Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. , 2012, Biochemical and biophysical research communications.

[11]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[12]  W. Fujibuchi,et al.  MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 , 2011, Molecular Cancer Research.

[13]  N. Seki,et al.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer , 2011, British Journal of Cancer.

[14]  Michael W. Pfaffl,et al.  Normalization Strategies for Microrna Profiling Experiments: a 'normal' Way to a Hidden Layer of Complexity? , 2010 .

[15]  M. Knowles,et al.  Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. , 2010, Urologic oncology.

[16]  N. Seki,et al.  821 MIR-145 AND MIR-133A FUNCTION AS TUMOUR SUPPRESSORS AND DIRECTLY REGULATE FSCN1 EXPRESSION IN BLADDER CANCER , 2010 .

[17]  N. Seki,et al.  miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer , 2010, British Journal of Cancer.

[18]  M. Duffy,et al.  Role of ADAMs in Cancer Formation and Progression , 2009, Clinical Cancer Research.

[19]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[20]  C. Cordon-Cardo Molecular alterations associated with bladder cancer initiation and progression , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[21]  Wayne Tam,et al.  MicroRNAs in tumorigenesis: a primer. , 2007, The American journal of pathology.

[22]  F. Marshall,et al.  Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. , 2006, Cancer research.

[23]  Michael W Pfaffl,et al.  RNA integrity and the effect on the real-time qRT-PCR performance. , 2006, Molecular aspects of medicine.

[24]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[25]  C. Blobel,et al.  Critical function for ADAM9 in mouse prostate cancer. , 2005, Cancer research.

[26]  M. Knowles,et al.  Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.

[27]  T. Libermann,et al.  A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. , 2005, Cancer research.

[28]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[29]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.

[30]  S. Yamamoto,et al.  Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis , 2004, Cancer Research.

[31]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[32]  M. Duffy,et al.  Expression of ADAM‐9 mRNA and protein in human breast cancer , 2003, International journal of cancer.

[33]  G. Baffet,et al.  ADAM12 in human liver cancers: TGF‐β‐regulated expression in stellate cells is associated with matrix remodeling , 2003, Hepatology.

[34]  L. Moore,et al.  Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest , 2000, Oncogene.

[35]  François G. Meyer,et al.  Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. , 1999, The American journal of pathology.

[36]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[37]  C. Cordon-Cardo,et al.  Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. , 1996, The American journal of pathology.

[38]  M. Knowles,et al.  Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. , 1991, Oncogene.

[39]  C. Cordon-Cardo,et al.  Molecular genetic alterations in superficial and locally advanced human bladder cancer. , 1991, Cancer research.